Related Experiment Video
Updated: Jan 20, 2026

Sonodynamic Therapy for the Treatment of Glioblastoma Multiforme in a Mouse Model Using a Portable Benchtop Focused Ultrasound System
Published on: February 10, 2023
Current promising treatment strategy for glioblastoma multiform: A review
Sanjib Bahadur1, Arvind Kumar Sahu1, Pragya Baghel1
1Department of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, Chhattisgarh, India.
Abstract:
Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.
Insights
Glioblastoma multiform (GBM) is a deadly brain cancer resistant to temozolomide (TMZ). This review explores new pharmaceutical candidates to overcome TMZ resistance and improve survival for GBM patients.
Area of Science:
- Neuro-oncology
- Cancer pharmacology
- Drug resistance mechanisms
Background:
- Glioblastoma multiform (GBM) is an aggressive brain tumor with poor prognosis.
- Current treatments including surgery, radiation, and chemotherapy have limited efficacy.
- Temozolomide (TMZ) is the standard chemotherapy, but resistance often develops.
Purpose of the Study:
- To review novel pharmaceutical candidates for GBM treatment.
- To explore strategies to overcome temozolomide (TMZ) resistance.
- To enhance the therapeutic efficacy of TMZ in glioblastoma.
Main Methods:
- Literature review of recent advancements in GBM targeted therapy.
- Analysis of drug resistance mechanisms involving O6-methylguanine-DNA methyltransferase (MGMT).
- Identification of promising pharmaceutical agents and conjugated strategies.
Main Results:
- Temozolomide resistance is a major challenge in GBM treatment.
- Specific pharmaceutical candidates show potential in overcoming resistance.
- Targeted therapy approaches can enhance TMZ efficacy.
Conclusions:
- New pharmaceutical strategies are crucial for improving GBM outcomes.
- Overcoming TMZ resistance is key to enhancing patient survival.
- Targeted therapies offer a promising avenue for future GBM treatment.
Related Concept Videos
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Electrical Current
Significance of Displacement Current
Current Trends in Nursing I

